<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomol Ther (Seoul)</journal-id><journal-id journal-id-type="iso-abbrev">Biomol Ther (Seoul)</journal-id><journal-title-group><journal-title>Biomolecules &#x00026; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">1976-9148</issn><issn pub-type="epub">2005-4483</issn><publisher><publisher-name>The Korean Society of Applied Pharmacology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35794797</article-id><article-id pub-id-type="pmc">PMC9424334</article-id><article-id pub-id-type="doi">10.4062/biomolther.2022.022</article-id><article-id pub-id-type="publisher-id">bt-30-5-435</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>CKD-581 Downregulates Wnt/&#x003b2;-Catenin Pathway by DACT3 Induction in Hematologic Malignancy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Soo Jin</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Suntae</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Yong June</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>U Ji</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kang</surname><given-names>Keon Wook</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, <country>Republic of Korea</country></aff><aff id="aff2"><label>2</label>CKD Research Institution, Chong Kun Dang Pharmaceutical Corporation, Yongin 16995, <country>Republic of Korea</country></aff><author-notes><corresp id="cor1"><label>*</label><bold>Corresponding Author</bold> E-mail: <email xlink:href="kwkang@snu.ac.kr">kwkang@snu.ac.kr</email>, Tel: +82-2-2880-7851, Fax: +82-2-2872-1795</corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>9</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>4</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>7</month><year>2022</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>30</volume><issue>5</issue><fpage>435</fpage><lpage>446</lpage><history><date date-type="received"><day>11</day><month>2</month><year>2022</year></date><date date-type="rev-recd"><day>10</day><month>5</month><year>2022</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2022</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2022, The Korean Society of Applied Pharmacology</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The present study evaluated the anti-cancer activity of histone deacetylase (HDAC)-inhibiting CKD-581 in multiple myeloma (MM) and its pharmacological mechanisms. CKD-581 potently inhibited a broad spectrum of HDAC isozymes. It concentration-dependently inhibited proliferation of hematologic cancer cells including MM (MM.1S and RPMI8226) and T cell lymphoma (HH and MJ). It increased the expression of the dishevelled binding antagonist of &#x003b2;-catenin 3 (DACT3) in T cell lymphoma and MM cells, and decreased the expression of c-Myc and &#x003b2;-catenin in MM cells. Additionally, it enhanced phosphorylated p53, p21, cleaved caspase-3 and the subG1 population, and reversely, downregulated cyclin D1, CDK4 and the anti-apoptotic BCL-2 family. Finally, administration of CKD-581 exerted a significant anti-cancer activity in MM.1S-implanted xenografts. Overall, CKD-581 shows anti-cancer activity via inhibition of the Wnt/&#x003b2;-catenin signaling pathway in hematologic malignancies. This finding is evidence of the therapeutic potential and rationale of CKD-581 for treatment of MM.</p></abstract><kwd-group><kwd>CKD-581</kwd><kwd>DACT3</kwd><kwd>HDAC</kwd><kwd>Wnt/&#x003b2;-catenin pathway</kwd><kwd>Hematologic cancer</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Multiple myeloma (MM) is a cancer originating from plasma cells (<xref rid="ref2" ref-type="bibr">Bergsagel and Kuehl, 2005</xref>). MM is the second most frequent hematologic malignancy; approximately 10% of the all hematologic malignancy patients are diagnosed with MM (<xref rid="ref41" ref-type="bibr">Rajkumar <italic>et al</italic>., 2014</xref>). Although the survival rate of patients has been improved due to the development of effective agents such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, MM patients eventually become resistant to all forms of chemotherapies (<xref rid="ref10" ref-type="bibr">de la Puente <italic>et al</italic>., 2014</xref>; <xref rid="ref15" ref-type="bibr">Giuliani <italic>et al</italic>., 2019</xref>; <xref rid="ref21" ref-type="bibr">Imai <italic>et al</italic>., 2019</xref>). Hence, new therapeutic options for resistant patients are urgently needed.</p><p>The diverse roles of epigenetic modifications of DNA and histones in cancer development have been extensively studied (<xref rid="ref31" ref-type="bibr">Li and Seto, 2016</xref>). Among them, histone acetylation is controlled by two enzymes, histone acetyltransferase (HAT) and histone deacetylases (HDAC) (<xref rid="ref46" ref-type="bibr">Sanchez <italic>et al</italic>., 2011</xref>; <xref rid="ref50" ref-type="bibr">Singh <italic>et al</italic>., 2018</xref>). HATs are enzymes that acetylate lysine residues of the target proteins, and HDACs remove acetyl groups from lysine residues (<xref rid="ref50" ref-type="bibr">Singh <italic>et al</italic>., 2018</xref>). Imbalances between HAT and HDAC activities are associated to the development and progression of many cancers (<xref rid="ref46" ref-type="bibr">Sanchez <italic>et al</italic>., 2011</xref>; <xref rid="ref9" ref-type="bibr">Dawson and Kouzarides, 2012</xref>). Also, loss of acetylation and aberrant expression of various HDACs seem to be related to poor prognosis in cancer patients. For example, loss of acetylation in histone H4 lysine 16 (H4K16) is considered to be a tumor hallmark (<xref rid="ref13" ref-type="bibr">Fraga <italic>et al</italic>., 2005</xref>) and a predictive marker of poor prognosis in breast cancer (<xref rid="ref11" ref-type="bibr">Elsheikh <italic>et al</italic>., 2009</xref>). Moreover, high expression levels of HDAC1, 2 and 3 are closely related to poor outcomes in ovarian and gastric cancer patients (<xref rid="ref58" ref-type="bibr">Weichert <italic>et al</italic>., 2008a</xref>, <xref rid="ref59" ref-type="bibr">2008b</xref>). In MM, dysregulation of histone acetylation is also believed to be a critical pathogenic process (<xref rid="ref21" ref-type="bibr">Imai <italic>et al</italic>., 2019</xref>). HDACs are frequently overexpressed in plasma cells sampled from MM patients (<xref rid="ref65" ref-type="bibr">Yuan <italic>et al</italic>., 2019</xref>), and higher HDAC expression is correlated with poor overall-survival and progression-free survival outcomes in MM patients (<xref rid="ref34" ref-type="bibr">Mithraprabhu <italic>et al</italic>., 2014</xref>). Hence, it has been suggested that HDACs are an attractive therapeutic target for MM treatment (<xref rid="ref51" ref-type="bibr">Sivaraj <italic>et al</italic>., 2017</xref>).</p><p>CKD-581 is a pan-HDAC inhibitor that targets class I&#x02013;II HDACs (<xref rid="ref27" ref-type="bibr">Kim <italic>et al</italic>., 2020</xref>). A phase I clinical study was conducted to evaluate the safety and tolerability of CKD-581 for patients with lymphoma and MM. CKD-581 was well tolerated, and 44.4% patients achieved a stable disease (SD) or better (<xref rid="ref7" ref-type="bibr">Cho <italic>et al</italic>., 2018</xref>). CKD-581 combination with standard chemotherapy was evaluated in patients with previously-treated MM. Combination of CKD-581, lenalidomide and dexamethasone was safe and objective response rate (ORR) was 70% (<xref rid="ref33" ref-type="bibr">Min <italic>et al</italic>., 2019</xref>).</p><p>Wnt/&#x003b2;-catenin signal transduction plays a critical role in the regulation of cell proliferation, differentiation and apoptosis in MM cells (<xref rid="ref28" ref-type="bibr">Kim <italic>et al</italic>., 2011</xref>). Dishevelled binding antagonist of &#x003b2;-catenin 3 (DACT3) is known to be a key regulator of Wnt/&#x003b2;-catenin signaling in esophageal squamous cell carcinoma, colorectal, breast and lung cancer types (<xref rid="ref23" ref-type="bibr">Jiang <italic>et al</italic>., 2008</xref>; <xref rid="ref60" ref-type="bibr">Xi <italic>et al</italic>., 2010</xref>; <xref rid="ref1" ref-type="bibr">Beltran <italic>et al</italic>., 2011</xref>; <xref rid="ref43" ref-type="bibr">Ren <italic>et al</italic>., 2017</xref>; <xref rid="ref67" ref-type="bibr">Zhao <italic>et al</italic>., 2017</xref>). Notwithstanding a recent report demonstrating DACT3 to be a negative regulator of the Wnt/&#x003b2;-catenin pathway (<xref rid="ref23" ref-type="bibr">Jiang <italic>et al</italic>., 2008</xref>), HDAC-dependent DACT3 regulation and its function on the Wnt/&#x003b2;-catenin pathway have yet to be studied in hematologic malignancies. In the present study, we revealed that CKD-581 (alteminostat), a novel pan-HDAC inhibitor, downregulated oncoproteins with DACT3 induction in MM cells, and further, we elucidated its pharmacological effectiveness in MM xenograft experiments.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Antibodies and compounds</title><p>Suberoylanilide hydroxamic acid (SAHA, Vorinostat) was obtained from Sigma-Aldrich (St. Louis, MO, USA). CKD-581 (purity 98.80%, M.W. 588.72) was supplied from CKD Pharmaceutical Corporation (Seoul, Korea). CellTiter-Glo luminescent cell viability assay kit was purchased from Promega (Madison, WI, USA). Antibodies recognizing DACT1, DACT3, &#x003b2;-catenin, Cyclin D1, CDK4, p53, BCL-xL and BCL-2 were supplied from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies against histone H3, acetylated histone H3, histone H4, acetylated histone H4, acetylated tubulin, p21, phospho-p53 cleaved-caspase 3, AKT, phospho-AKT, p70S6K, phospho-p70S6K (Thr389), mTOR and phospho-mTOR (Ser2448) were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies targeting DACT2, c-Myc and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from Thermo Fisher Scientific (Waltham, MA, USA).</p></sec><sec><title>HDAC enzyme assay</title><p><italic>In vitro</italic> HDAC enzyme assays were performed by Reaction Biology Corporation (Malvern, PA, USA). Ten points dose response curve for CKD-581 was evaluated for each HDAC isozymes. IC<sub>50</sub> values for HDAC isozymes were calculated using the GraphPad Prism 5 program (Irvine, CA, USA). The values are presented as average of at least three different experiments.</p></sec><sec><title>Cell culture</title><p>Human multiple myeloma cell lines (MM.1S and RPMI8226) and human T cell lymphoma cell lines (HH and MJ) were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). MM.1S, RPMI8226 and HH cells were cultured in RPMI-1640 medium (Thermo Fisher Scientific) that is supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific) at 37&#x000b0;C in 5% CO<sub>2</sub>. MJ cells were cultured in Iscove&#x02019;s modified Dulbecco&#x02019;s medium (IMDM, Thermo Fisher Scientific) containing 20% FBS.</p></sec><sec><title>Cell proliferation assay</title><p>Cells cultured in 96-well plates were treated with vehicle (0.1% DMSO), CKD-581 or SAHA. Cell viability was determined by CellTiter-Glo assay system (Promega) 72 h after compound treatment. Luminescence was determined using FlexStation 3 (Molecular Devices, San Jose, CA, USA).</p></sec><sec><title>Histone protein extraction</title><p>Histone proteins were extracted in MM.1S cells treated with CKD-581 or SAHA for 6 h. Histone protein extraction was performed as previously described (<xref rid="ref27" ref-type="bibr">Kim <italic>et al</italic>., 2020</xref>). The extracted proteins were subjected to analysis of histone protein acetylation status.</p></sec><sec><title>cDNA microarray and gene expression analysis</title><p>Total RNA was isolated and purified using Trizol (Thermo Fisher Scientific) and RNeasy Mini Kit (Qiagen, Hilden, NRW, Germany), respectively. The microarray hybridization was performed using the Infinium<sup>&#x000ae;</sup> HumanHT-12 BeadChip (Illumina, San Diego, CA, USA). Analyses and figure generation were conducted using R (<ext-link xlink:href="https://www.r-project.org/" ext-link-type="uri">https://www.r-project.org/</ext-link>, version 3.5.2). Raw data were normalized using quantile algorithm and heatmaps were plotted using heatmap.2 from gplots R package (<ext-link xlink:href="https://cran.r-project.org/web/packages/gplots/index.html" ext-link-type="uri">https://cran.r-project.org/web/packages/gplots/index.html</ext-link>, version 3.0.1.1).</p></sec><sec><title>Western blot analysis</title><p>Cell lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich) supplemented with protease and phosphatase inhibitor cocktail (Roche, Basel, Switzerland). BCA protein assay kit (Thermo Fisher Scientific) was used for quantification of protein concentration. Western blotting was performed as previously described (<xref rid="ref27" ref-type="bibr">Kim <italic>et al</italic>., 2020</xref>). GAPDH was used for normalization of all immunoblot results. ChemiDoc (Biorad, Hercules, CA, USA) was used to detect chemiluinescence signals.</p></sec><sec><title>Flow cytometry analysis</title><p>MM.1S and RPMI8226 cells were incubated with vehicle or CKD-581 for 24 h. Cells were harvested and fixed with 70% ethanol in phosphate-buffered saline at &#x02013;20&#x000b0;C for 24 h. The fixed cells were stained with propidium iodide staining solution at room temperature, and the stained cells were analyzed by flow cytometry (FACSCalibur, BD Bioscience, NJ, USA).</p></sec><sec><title>Xenograft assay</title><p>All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of CKD Research Institute (Approval # S014-037, July 21, 2014). Six-week-old NOD.CB17 SCID mice were subcutaneously implanted with 2&#x000d7;10<sup>7</sup> MM.1S cells suspended in Matrigel (Trevigen, Gaithersburg, MD, USA). Tumor volume and body weight gain were monitored two times per week.</p></sec><sec><title>Statistical analysis</title><p>One-way ANOVA was used to assess the differences in all experiments except tumor xenograft experiment. Two-way ANOVA or t-test was used for tumor xenograft experiment. Significance was expressed as *<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01, and ***<italic>p</italic>&#x0003c;0.001.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>HDAC inhibition by CKD-581</title><p>To investigate the inhibitory activities of CKD-581 (<xref rid="F1" ref-type="fig">Fig. 1A</xref>) on HDACs, <italic>In vitro</italic> HDAC inhibition assays using purified HDAC isozymes were conducted. CKD-581 treatment markedly inhibited most of the tested HDAC isozymes, and especially, it potently inhibited HDAC1, 2, 3, 6, 9, 10 and 11 at a concentration as low as 30 nM (<xref rid="T1" ref-type="table">Table 1</xref>). Further, the results of enzyme assays confirmed that CKD-581 is a potent pan-HDAC inhibitor (<xref rid="ref27" ref-type="bibr">Kim <italic>et al</italic>., 2020</xref>).</p><p>SAHA (Vorinostat<sup>&#x000ae;</sup>), a HDAC inhibitor, has been approved for the treatment of refractory cutaneous and peripheral T cell lymphoma (<xref rid="ref9" ref-type="bibr">Dawson and Kouzarides, 2012</xref>; <xref rid="ref50" ref-type="bibr">Singh <italic>et al</italic>., 2018</xref>). The acetylation intensity of histone H3 and H4 was increased following exposure to CKD-581 or SAHA in MM.1S cells. Additionally, the acetylation of tubulin also was increased by CKD-581 or SAHA, and the acetylation intensity was stronger by CKD-581 than by SAHA in histone H3 and H4 (<xref rid="F1" ref-type="fig">Fig. 1B</xref>). According to the overall results, CKD-581 potently inhibited both class I and class II HDAC enzyme activities and subsequently induced acetylation of target molecules in MM cells.</p></sec><sec><title>Suppression of cell viabilities of T cell lymphoma and MM cells by CKD-581</title><p>The inhibitory effects of CKD-581 on the cell viabilities of T cell lymphoma cell lines (HH and MJ) and MM cell lines (MM.1S and RPMI8226) were assessed using the CellTiter-Glo luminescent cell viability assay system. CKD-581 concentration-dependently inhibited the cell viabilities of the T cell lymphoma and MM cell lines. The IC<sub>50</sub> values of CKD-581 in HH, MJ, MM.1S and RPMI8226 were 32.9 &#x000b1; 1.3, 93.3 &#x000b1; 4.2, 38.8 &#x000b1; 1.3 and 53.3 &#x000b1; 5.0 nM, respectively (<xref rid="F1" ref-type="fig">Fig. 1C</xref>). Moreover, The IC<sub>50</sub> values of CKD-581 were at least 6-fold lower than those of SAHA. The data indicated that CKD-581 had potently induced cancer cell death in both T cell lymphoma and MM cells.</p></sec><sec><title>Selective induction of DACT3 by CKD-581 and subsequent inhibition of Wnt/&#x003b2;-catenin signaling</title><p>To characterize the pharmacological mechanism of the anti-cancer activities of CKD-581 in hematologic malignancies, a cDNA microarray was performed in the two T cell lymphoma cell lines (HH and MJ cells) exposed to vehicle or CKD-581 for 6, 12 and 24 h. The mRNA expression patterns were analyzed by Infinium<sup>&#x000ae;</sup> HumanHT-12 BeadChip (48K probes). Heatmap analysis of the gene expression profiles showed that the genes related to the Wnt/&#x003b2;-catenin pathway were significantly affected by CKD-581 treatment (<xref rid="F2" ref-type="fig">Fig. 2A</xref>). Wnt/&#x003b2;-catenin signaling is one of the key signaling pathways for control of the development and stemness of cancer in hematologic malignancies (<xref rid="ref56" ref-type="bibr">Wang <italic>et al</italic>., 2009</xref>). Interestingly, DACT3 expression was most distinctly increased in the two cell lines at all of the tested time points (<xref rid="F2" ref-type="fig">Fig. 2A</xref>).</p><p>Genes of which the expression levels increased or decreased by CKD-581 more than 4-fold relative to vehicle-treated control samples were selected from cDNA microarray data. A total of 19 genes were identified as down-regulated and 9 genes as up-regulated by CKD-581 in HH cells, at 3 time points commonly. In the case of MJ cells, there was no commonly down-regulated gene, and only one gene, DACT3, was identified as up-regulated by CKD-581 treatment at the three different time points. Therefore, DACT3 was the only gene modulated by CKD-581 in both cell types and at all time points (<xref rid="S1" ref-type="supplementary-material">Supplementary Fig. 1A</xref>).</p><p>DACT3 is known to be an epigenetic regulator of Wnt/&#x003b2;-catenin signaling in colorectal cancer (<xref rid="ref23" ref-type="bibr">Jiang <italic>et al</italic>., 2008</xref>) and non-small cell lung cancer (NSCLC) (<xref rid="ref67" ref-type="bibr">Zhao <italic>et al</italic>., 2017</xref>). It has been reported that DACT3 expression is regulated by histone modifications (<xref rid="ref23" ref-type="bibr">Jiang <italic>et al</italic>., 2008</xref>). To further confirm whether CKD-581 induces DACT3 in MM cell lines, the protein expression levels of the DACT family were determined in CKD-581- or SAHA-treated MM.1S cells. The protein expression of DACT3 was significantly enhanced by 300 nM CKD-581 or 3000 nM SAHA (<xref rid="F2" ref-type="fig">Fig. 2B</xref>), and the protein expression of DACT3 was increased in a time-dependent manner (<xref rid="F2" ref-type="fig">Fig. 2C</xref>). Notably, the protein expression of the other two DACT family members, DACT1 and DACT2, was not altered by CKD-581 or SAHA in MM.1S cells. We also found that, in RPMI8226 cells, DACT3 was induced by 300 and 1000 nM CKD-581 but not by 1000 nM SAHA (<xref rid="F2" ref-type="fig">Fig. 2B</xref>).</p><p>We then tested the effects of CKD-581 on the expression of &#x003b2;-catenin and c-Myc, which are representative downstream target genes of the Wnt/&#x003b2;-catenin pathway in MM cells. As expected, CKD-581 markedly decreased the protein levels of &#x003b2;-catenin and c-Myc in MM.1S and RPMI8226 cells, and its inhibition intensity was stronger than that of SAHA (<xref rid="F2" ref-type="fig">Fig. 2D</xref>). These results suggest that CKD-581 inactivates the Wnt/&#x003b2;-catenin pathway, presumably via DACT3 upregulation in MM cells.</p></sec><sec><title>Downregulation of cyclin D1/CDK4 and apoptosis induction by CKD-581</title><p>Overexpression of &#x003b2;-catenin is known to increase the expression of several target oncogenes such as <italic>CCND1</italic> and <italic>c-myc</italic> (<xref rid="ref61" ref-type="bibr">Xi and Chen, 2014</xref>). Cyclin D1 is a key regulator of the cell cycle for stimulation of S-phase entry of cells from the G<sub>1</sub> phase in human cancer (<xref rid="ref38" ref-type="bibr">Musgrove <italic>et al</italic>., 2011</xref>; <xref rid="ref54" ref-type="bibr">VanArsdale <italic>et al</italic>., 2015</xref>; <xref rid="ref40" ref-type="bibr">Qie and Diehl, 2016</xref>). D cyclins form active complex with either CDK4 or CDK6, which drives the G<sub>1</sub>-to-S-phase transition (<xref rid="ref38" ref-type="bibr">Musgrove <italic>et al</italic>., 2011</xref>; <xref rid="ref40" ref-type="bibr">Qie and Diehl, 2016</xref>). Immunoblotting results showed that treatment of the MM cell lines (MM.1S and RPMI8226) with CKD-581 decreased the levels of cyclin D1 and CDK4 in a concentration- and time-dependent manners (<xref rid="F3" ref-type="fig">Fig. 3A</xref>, <xref rid="F3" ref-type="fig">3B</xref>). SAHA also reduced the expression level of CDK4 and Cyclin D1 at higher concentration ranges in the MM.1S cells. However, when we performed cell-cycle analyses in MM.1S and RPMI8226 cells incubated with CKD-581 for 24 h, we could not determine G<sub>1</sub>/S arrest in either cell type (<xref rid="F3" ref-type="fig">Fig. 3C</xref>). On the contrary, CKD-581 significantly increased the sub-G<sub>1</sub> portion in concentration-dependent manners in both MM.1S and RPMI8226 cells (<xref rid="F3" ref-type="fig">Fig. 3C</xref>). Relative to the vehicle-treated control cells, the sub-G<sub>1</sub> population increased from 5.45 &#x000b1; 0.16% to 22.65 &#x000b1; 1.43 and 26.61 &#x000b1; 1.80% in MM.1S cells following exposure to 300 and 1000 nM CKD-581 for 24 h, respectively (<italic>p</italic>&#x0003c;0.001). We further found that CKD-581 concentration-dependently increased the formation of cleaved caspase-3 after 24 h incubation in MM.1S and RPMI8226 cells (<xref rid="F3" ref-type="fig">Fig. 3D</xref>). However, 1000 nM SAHA only marginally increased the cleaved caspase-3 in RPMI8226 cells (<xref rid="F3" ref-type="fig">Fig. 3D</xref>). The data imply that CKD-581 may cause apoptosis via suppression of the Wnt/&#x003b2;-catenin pathway in hematologic cancer cells.</p></sec><sec><title>p53/p21 activation and BCL-xL inactivation by CKD-581 in MM cells</title><p>Because &#x003b2;-catenin and c-Myc are related to regulation of p53 phosphorylation, inhibition of the Wnt/&#x003b2;-catenin pathway induces apoptotic cell death in cancer cells (<xref rid="ref45" ref-type="bibr">Riascos-Bernal <italic>et al</italic>., 2016</xref>; <xref rid="ref29" ref-type="bibr">Kwak <italic>et al</italic>., 2018</xref>). To determine whether the increased sub-G<sub>1</sub> population mainly results from the activation of the p53 pathway, p53 and downstream effectors were analyzed by immunoblottings. Ser<sup>15</sup> phosphorylation of p53 is critical to proper functioning of p53 as a transcription factor, and p53 activation controls the diverse proteins related to DNA repair and apoptosis, including p21 and the BCL-2 family (<xref rid="ref55" ref-type="bibr">Vousden, 2000</xref>). Among them, p21 plays a crucial role in the induction of cell-cycle arrest by acting as an inhibitor of CDKs. As shown in <xref rid="F4" ref-type="fig">Fig. 4A</xref>, CKD-581 increased the level of p21 in MM cells. The expression of p21 was correlated with increased Ser<sup>15</sup> phosphorylation of p53 (<xref rid="F4" ref-type="fig">Fig. 4A</xref>). Under the transcriptional regulation of p53, BCL-2 family proteins also are involved in control of apoptosis (<xref rid="ref5" ref-type="bibr">Burger <italic>et al</italic>., 1998</xref>). BCL-xL protein expression was downregulated by CKD-581 in both MM.1S and RPMI8226 cells (<xref rid="F4" ref-type="fig">Fig. 4B</xref>). However, BCL-2 was only marginally affected by CKD-581 (<xref rid="F4" ref-type="fig">Fig. 4B</xref>). It supportedthat CKD-581 increased the expression of tumor suppressor genes, which led in turn to MM cell death via apoptosis.</p></sec><sec><title>Anti-cancer effect of CKD-581 in MM xenograft model</title><p>SCID mice bearing MM.1S cells were used to assess the <italic>in vivo</italic> anti-cancer effect of CKD-581 on MM. CKD-581 (40 and 60 mg/kg) or vehicle (normal saline) were intraperitoneally injected twice per week. As depicted in <xref rid="F5" ref-type="fig">Fig. 5A</xref> and <xref rid="F5" ref-type="fig">5B</xref>, the tumor sizes of the CKD-581-treated groups were significantly diminished relative to the vehicle-treated group (<italic>p</italic>&#x0003c;0.001). Although the CKD-581 groups showed slightly smaller body-weight gains (<xref rid="F5" ref-type="fig">Fig. 5C</xref>), there was no symptomatic toxicity. Thus, we assumed that the smaller body weight gains by CKD-581 treatment may have resulted from the reduced tumor sizes.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>CKD-581, a novel HDAC inhibitor, is an efficacious anti-cancer agent in patients suffering from lymphoma or MM (<xref rid="ref7" ref-type="bibr">Cho <italic>et al</italic>., 2018</xref>). Currently, two clinical trials with MM patients are ongoing (NCT03051841, NCT03150316). Although we have reported that CKD-581 showed anti-cancer activity against diffuse large B cell lymphoma (DLBCL) (<xref rid="ref27" ref-type="bibr">Kim <italic>et al</italic>., 2020</xref>), the pharmacological mechanism of CKD-581-induced cancer cell death has yet to be studied in MM. In this study, we showed that CKD-581 induced apoptosis via suppression of the Wnt/&#x003b2;-catenin pathway in MM cells. Several studies have suggested that the Wnt/&#x003b2;-catenin pathway could be a possible therapeutic target for inhibition of cancer progression, metastasis, chemo-resistance and immunosurveillance evasion (<xref rid="ref61" ref-type="bibr">Xi and Chen, 2014</xref>; <xref rid="ref64" ref-type="bibr">Yuan <italic>et al</italic>., 2020</xref>). The Wnt/&#x003b2;-catenin pathway also plays a crucial role in the progression of hematologic cancers (<xref rid="ref52" ref-type="bibr">Spaan <italic>et al</italic>., 2018</xref>). In MM, &#x003b2;-catenin silencing caused induction of apoptosis as well as recovery of lenalidomide sensitivity (<xref rid="ref3" ref-type="bibr">Bjorklund <italic>et al</italic>., 2011</xref>; <xref rid="ref53" ref-type="bibr">Su <italic>et al</italic>., 2016</xref>). However, the physiological role of Wnt/&#x003b2;-catenin signaling would differ by cancer type. Unlike most cancer types, wherein Wnt/&#x003b2;-catenin is crucial to tumorigenesis, the opposite aspects have been shown in several cancer types. For instance, low &#x003b2;-catenin levels are related to poor prognosis in melanoma and pancreatic ductal adenocarcinoma (PDAC) patients (<xref rid="ref6" ref-type="bibr">Chien <italic>et al</italic>., 2009</xref>; <xref rid="ref47" ref-type="bibr">Saukkonen <italic>et al</italic>., 2016</xref>). HDAC inhibitors, such as sodium butyrate, trichostatin A, suberoyl bis-hydroxamic acid and valproic acid, induced apoptosis via hyperactivation of Wnt/&#x003b2;-catenin in solid or hematologic cancer (<xref rid="ref4" ref-type="bibr">Bordonaro <italic>et al</italic>., 2007</xref>; <xref rid="ref48" ref-type="bibr">Shao <italic>et al</italic>., 2012</xref>). Although the pathological functions on the Wnt/&#x003b2;-catenin pathway remain controversial, HDAC inhibitors show anti-cancer activity regardless of cancer type. This phenomenon may reflect the multiple functions of the HDAC family and/or the variable mutations involved in the Wnt/&#x003b2;-catenin pathway. For instance, diverse targets regulating proliferation, differentiation and cell death are simultaneously affected by HDACs (<xref rid="ref16" ref-type="bibr">Gong <italic>et al</italic>., 2019</xref>). Thus, the therapeutic effects of HDAC inhibitors could be the sum of complicated factors on various pathways. Additionally, mutations in adenomatous polyposis coli (APC) and &#x003b2;-catenin induce constitutive activation of canonical Wnt/&#x003b2;-catenin signaling in colon cancer (<xref rid="ref37" ref-type="bibr">Munemitsu <italic>et al</italic>., 1995</xref>; <xref rid="ref36" ref-type="bibr">Morin <italic>et al</italic>., 1997</xref>), which may cause HDAC-independent activity changes in the signaling pathway.</p><p>The DACT family, consisting of DACT1, DACT2 and DACT3, is known to be a functional suppressor group for the Wnt/&#x003b2;-catenin pathway during embryonic development and carcinogenesis (<xref rid="ref12" ref-type="bibr">Fisher <italic>et al</italic>., 2006</xref>; <xref rid="ref23" ref-type="bibr">Jiang <italic>et al</italic>., 2008</xref>; <xref rid="ref32" ref-type="bibr">Mandal and Waxman, 2014</xref>; <xref rid="ref67" ref-type="bibr">Zhao <italic>et al</italic>., 2017</xref>). Especially, DACT3 expression can be regulated by histone modification such as acetylation or methylation (<xref rid="ref23" ref-type="bibr">Jiang <italic>et al</italic>., 2008</xref>). However, up to now, nothing is known about the function of HDAC-inhibitor-mediated DACT3 regulation in MM. In these pages, we have reported that CKD-581 and SAHA suppressed the Wnt/&#x003b2;-catenin pathway by selective induction of DACT3. Hence, it is plausible that the Wnt/&#x003b2;-catenin signaling pathway is regulated by HDAC inhibitors via DACT3 overexpression in MM. However, the precise regulation mechanism of interaction between DACT3 and HDAC needs to be clarified in future studies.</p><p>In the present study, we determined that CKD-581 induced apoptosis in the tested MM cell lines, though cell-cycle arrest was not seen up to 1 &#x000b5;M CKD-581. c-Myc, a representative target gene of the Wnt/&#x003b2;-catenin pathway, is known to be a potent oncogene (<xref rid="ref14" ref-type="bibr">Gabay <italic>et al</italic>., 2014</xref>; <xref rid="ref44" ref-type="bibr">Rennoll and Yochum, 2015</xref>). In fact, several HDAC inhibitors reduce c-Myc expression and increase apoptotic cell death in cancer cells (<xref rid="ref39" ref-type="bibr">Nebbioso <italic>et al</italic>., 2017</xref>; <xref rid="ref49" ref-type="bibr">Shieh <italic>et al</italic>., 2017</xref>). For example, it was reported that c-Myc increases Bcl-xL expression through lncRNA H19 and STAT5 activation in leukemia (<xref rid="ref17" ref-type="bibr">Guo <italic>et al</italic>., 2014</xref>), and that loss of Bcl-xL prevents c-Myc-induced lymphomatogenesis (<xref rid="ref25" ref-type="bibr">Kelly <italic>et al</italic>., 2011</xref>). Therefore, Bcl-xL upregulation coinciding with limited apoptosis may be actively involved in c-Myc-driven tumor progression. In this study, HDAC inhibitors (CKD-581 and SAHA) efficiently decreased the expression of c-Myc and BCL-xL in MM cells (<xref rid="F2" ref-type="fig">Fig. 2D</xref>, <xref rid="F4" ref-type="fig">4B</xref>).</p><p>Wnt/&#x003b2;-catenin activation suppresses p53 function. Active &#x003b2;-catenin abrogated the transcriptional activity of p53, and inactivation of &#x003b2;-catenin by XAV939 increased the p53 acetylation and transcriptional activity in smooth muscle cells (<xref rid="ref45" ref-type="bibr">Riascos-Bernal <italic>et al</italic>., 2016</xref>). Also, it is known that the Wnt/&#x003b2;-catenin signaling pathway inhibits expression of p53 via miR-552 in colorectal cancers (<xref rid="ref29" ref-type="bibr">Kwak <italic>et al</italic>., 2018</xref>). Therefore, it seems certain that inhibition of the Wnt/&#x003b2;-catenin axis by CKD-581 affects p53, a representative tumor suppressor gene. In fact, the protein level of Ser<sup>15</sup>-phosphorylated p53 was enhanced by CKD-581 without change to total p53 expression (<xref rid="F4" ref-type="fig">Fig. 4B</xref>). Both Ser<sup>15</sup>-phosphorylated p53 and p21 expression are known to be good prognostic markers in cancer (<xref rid="ref24" ref-type="bibr">Kao <italic>et al</italic>., 2007</xref>; <xref rid="ref63" ref-type="bibr">Yang <italic>et al</italic>., 2019</xref>). Thus, the pharmacological features of CKD-581 for activation of tumor suppressor genes p53 and p21 would be involved in its anti-cancer effects against MM.</p><p>The AKT/mTOR signaling pathway is one of the well-known cancer-related pathways that regulate cell proliferation, survival, metabolism and immunity (<xref rid="ref30" ref-type="bibr">Leal <italic>et al</italic>., 2013</xref>; <xref rid="ref20" ref-type="bibr">Hua <italic>et al</italic>., 2019</xref>), and crosstalk between the AKT/mTOR and Wnt/&#x003b2;-catenin pathway has been reported (<xref rid="ref8" ref-type="bibr">Daisy Precilla <italic>et al</italic>., 2022</xref>). In addition, mTOR is believed as a therapeutic target for anti-cancer therapy. Because HDAC inhibitors suppress the AKT/mTOR signaling pathway in cancer cells (<xref rid="ref66" ref-type="bibr">Zhang <italic>et al</italic>., 2015</xref>), we tested whether CKD-581 affects the AKT/mTOR pathway. CKD-581 decreased phosphorylation of mTOR and 70 kDa ribosomal protein S6 kinase (p70S6K) in MM cell lines (<xref rid="S1" ref-type="supplementary-material">Supplementary Fig. 1B</xref>), indicating that mTOR pathway inhibition is related with anti-cancer effects of CKD-581 in MM.</p><p>The intensity of tubulin acetylation induced by CKD-581 or SAHA was comparable (<xref rid="F1" ref-type="fig">Fig. 1B</xref>). Tubulins are subject to various post-translational modifications (PTMs), such as detyrosination, polyglutamylation, polyglycylation and acetylation (<xref rid="ref22" ref-type="bibr">Janke and Bulinski, 2011</xref>). It has been known that paclitaxel induces acetylation at Lys40 on the luminal surface of microtubules (<xref rid="ref19" ref-type="bibr">Howes <italic>et al</italic>., 2014</xref>). Paclitaxel stimulates Lys40 acetylation of tubulin and stabilizes myeloid cell leukemia-1 (MCL-1), an anti-apoptotic protein, which is related with chemoresistance (<xref rid="ref57" ref-type="bibr">Wattanathamsan <italic>et al</italic>., 2021</xref>). MCL-1 overexpression has been reported in various cancers, and down-regulation of MCL-1 increase the sensitivity to chemotherapies (<xref rid="ref62" ref-type="bibr">Xiang <italic>et al</italic>., 2018</xref>).</p><p>HDAC enzymes are able to remove the acetyl groups from various proteins. Whereas HDAC inhibitors increase the acetylation of the target proteins (<xref rid="ref26" ref-type="bibr">Kim and Bae, 2011</xref>). Although tubulin acetylation at Lys40 was increased by HDAC6 inhibition, MCL-1 and other anti-apoptotic proteins were down-regulated by pan- or class I HDAC inhibition (<xref rid="ref18" ref-type="bibr">He <italic>et al</italic>., 2013</xref>; <xref rid="ref42" ref-type="bibr">Ramakrishnan <italic>et al</italic>., 2019</xref>; <xref rid="ref27" ref-type="bibr">Kim <italic>et al</italic>., 2020</xref>). Hence, class I- or pan-HDAC inhibitors, including CKD-581 would increase the sensitivity to chemotherapy through MCL-1 down-regulation.</p><p>In comparison with SAHA, CKD-581 more potently induced acetylation of histone proteins. These results imply that CKD-581 more efficiently acetylates target proteins in class I HDACs. Because dysregulation of class I HDAC is correlated with poor prognosis in MM patients (<xref rid="ref34" ref-type="bibr">Mithraprabhu <italic>et al</italic>., 2014</xref>), and MM cell death is more prominent by class I HDAC inhibitors than class II HDAC inhibitors (<xref rid="ref35" ref-type="bibr">Mithraprabhu <italic>et al</italic>., 2013</xref>), CKD-581 is expected to be more effective than SAHA for treatment of MM. Safety is an important issue in new-drug development, particularly since combination therapy is considered to be a means of improving treatment efficacy for diverse cancer types. Thus far in clinical trials, CKD-581 has had an acceptable safety profile (<xref rid="ref7" ref-type="bibr">Cho <italic>et al</italic>., 2018</xref>).</p><p>In summary, CKD-581 is a potent HDAC inhibitor targeting types I and II HDACs. CKD-581 is highly effective in inhibiting proliferation of hematologic cancer cells including MM and T cell lymphoma. cDNA microarray and immunoblot analyses revealed that DACT3 overexpression-related downregulation of the Wnt/&#x003b2;-catenin pathway is correlated with CKD-581-induced cell death in hematologic cancer. Certainly, CKD-581 could be a useful HDAC inhibitor against hematologic cancers. Our present findings, furthermore, are meaningful in explicating the mechanistic basis of HDAC inhibitors&#x02019; anti-cancer effects.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This work was supported by the National Research Foundation of Korea (NRF) grant funded by Korean Government (2021R1A4A1021787).</p></ack><fn-group><fn fn-type="supplementary-material"><p>
<supplementary-material id="S1" position="float" content-type="local-data"><media xlink:href="bt-30-5-435-supple.pdf" id="d64e826" position="anchor"/></supplementary-material>
</p></fn><fn fn-type="COI-statement"><p>
<bold>CONFLICT OF INTEREST</bold>
</p><p>Soo Jin Kim and U Ji Kim works in CKD Research Institution, Chong Kun Dang Pharmaceutical Corporation.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beltran</surname><given-names>A. S.</given-names></name>
<name><surname>Russo</surname><given-names>A.</given-names></name>
<name><surname>Lara</surname><given-names>H.</given-names></name>
<name><surname>Fan</surname><given-names>C.</given-names></name>
<name><surname>Lizardi</surname><given-names>P. M.</given-names></name>
<name><surname>Blancafort</surname><given-names>P.</given-names></name>
</person-group><year>2011</year><article-title>Suppression of breast tumor growth and metastasis by an engineered transcription factor</article-title><source>PLoS ONE</source><volume>6</volume><elocation-id>e24595</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0024595</pub-id><!--<pub-id pub-id-type="pmcid">PMC3172243</pub-id>--><pub-id pub-id-type="pmid">21931769</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bergsagel</surname><given-names>P. L.</given-names></name>
<name><surname>Kuehl</surname><given-names>W. M.</given-names></name>
</person-group><year>2005</year><article-title>Molecular pathogenesis and a consequent classification of multiple myeloma</article-title><source>J. Clin. Oncol.</source><volume>23</volume><fpage>6333</fpage><lpage>6338</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.05.021</pub-id><pub-id pub-id-type="pmid">16155016</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bjorklund</surname><given-names>C. C.</given-names></name>
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>Z. Q.</given-names></name>
<name><surname>Davis</surname><given-names>R. E.</given-names></name>
<name><surname>Kuhn</surname><given-names>D. J.</given-names></name>
<name><surname>Kornblau</surname><given-names>S. M.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Shah</surname><given-names>J. J.</given-names></name>
<name><surname>Orlowski</surname><given-names>R. Z.</given-names></name>
</person-group><year>2011</year><article-title>Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide</article-title><source>J. Biol. Chem.</source><volume>286</volume><fpage>11009</fpage><lpage>11020</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.180208</pub-id><!--<pub-id pub-id-type="pmcid">PMC3064156</pub-id>--><pub-id pub-id-type="pmid">21189262</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bordonaro</surname><given-names>M.</given-names></name>
<name><surname>Lazarova</surname><given-names>D. L.</given-names></name>
<name><surname>Sartorelli</surname><given-names>A. C.</given-names></name>
</person-group><year>2007</year><article-title>The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors</article-title><source>Exp. Cell Res.</source><volume>313</volume><fpage>1652</fpage><lpage>1666</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2007.02.008</pub-id><!--<pub-id pub-id-type="pmcid">PMC3919021</pub-id>--><pub-id pub-id-type="pmid">17359971</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burger</surname><given-names>H.</given-names></name>
<name><surname>Nooter</surname><given-names>K.</given-names></name>
<name><surname>Boersma</surname><given-names>A. W.</given-names></name>
<name><surname>Kortland</surname><given-names>C. J.</given-names></name>
<name><surname>Stoter</surname><given-names>G.</given-names></name>
</person-group><year>1998</year><article-title>Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines</article-title><source>Br. J. Cancer</source><volume>77</volume><fpage>1562</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1038/bjc.1998.257</pub-id><!--<pub-id pub-id-type="pmcid">PMC2150079</pub-id>--><pub-id pub-id-type="pmid">9635829</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chien</surname><given-names>A. J.</given-names></name>
<name><surname>Moore</surname><given-names>E. C.</given-names></name>
<name><surname>Lonsdorf</surname><given-names>A. S.</given-names></name>
<name><surname>Kulikauskas</surname><given-names>R. M.</given-names></name>
<name><surname>Rothberg</surname><given-names>B. G.</given-names></name>
<name><surname>Berger</surname><given-names>A. J.</given-names></name>
<name><surname>Major</surname><given-names>M. B.</given-names></name>
<name><surname>Hwang</surname><given-names>S. T.</given-names></name>
<name><surname>Rimm</surname><given-names>D. L.</given-names></name>
<name><surname>Moon</surname><given-names>R. T.</given-names></name>
</person-group><year>2009</year><article-title>Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>106</volume><fpage>1193</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811902106</pub-id><!--<pub-id pub-id-type="pmcid">PMC2626610</pub-id>--><pub-id pub-id-type="pmid">19144919</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>H.</given-names></name>
<name><surname>Yoon</surname><given-names>D. H.</given-names></name>
<name><surname>Kim</surname><given-names>K. P.</given-names></name>
<name><surname>Bae</surname><given-names>K. S.</given-names></name>
<name><surname>Kim</surname><given-names>W. S.</given-names></name>
<name><surname>Eom</surname><given-names>H. S.</given-names></name>
<name><surname>Kim</surname><given-names>J. S.</given-names></name>
<name><surname>Hong</surname><given-names>J. Y.</given-names></name>
<name><surname>Kim</surname><given-names>S. J.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>S. J.</given-names></name>
<name><surname>Suh</surname><given-names>C.</given-names></name>
</person-group><year>2018</year><article-title>Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy</article-title><source>Invest. New Drugs</source><volume>36</volume><fpage>877</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1007/s10637-018-0582-0</pub-id><pub-id pub-id-type="pmid">29520651</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daisy Precilla</surname><given-names>S.</given-names></name>
<name><surname>Biswas</surname><given-names>I.</given-names></name>
<name><surname>Kuduvalli</surname><given-names>S. S.</given-names></name>
<name><surname>Anitha</surname><given-names>T. S.</given-names></name>
</person-group><year>2022</year><article-title>Crosstalk between PI3K/AKT/mTOR and WNT/beta-Catenin signaling in GBM - could combination therapy checkmate the collusion?</article-title><source>Cell. Signal.</source><volume>95</volume><elocation-id>110350</elocation-id><pub-id pub-id-type="doi">10.1016/j.cellsig.2022.110350</pub-id><pub-id pub-id-type="pmid">35525406</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dawson</surname><given-names>M. A.</given-names></name>
<name><surname>Kouzarides</surname><given-names>T.</given-names></name>
</person-group><year>2012</year><article-title>Cancer epigenetics: from mechanism to therapy</article-title><source>Cell</source><volume>150</volume><fpage>12</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.06.013</pub-id><pub-id pub-id-type="pmid">22770212</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de la Puente</surname><given-names>P.</given-names></name>
<name><surname>Muz</surname><given-names>B.</given-names></name>
<name><surname>Azab</surname><given-names>F.</given-names></name>
<name><surname>Luderer</surname><given-names>M.</given-names></name>
<name><surname>Azab</surname><given-names>A. K.</given-names></name>
</person-group><year>2014</year><article-title>Molecularly targeted therapies in multiple myeloma</article-title><source>Leuk. Res. Treatment</source><volume>2014</volume><elocation-id>976567</elocation-id><pub-id pub-id-type="doi">10.1155/2014/976567</pub-id><!--<pub-id pub-id-type="pmcid">PMC4009206</pub-id>--><pub-id pub-id-type="pmid">24829804</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elsheikh</surname><given-names>S. E.</given-names></name>
<name><surname>Green</surname><given-names>A. R.</given-names></name>
<name><surname>Rakha</surname><given-names>E. A.</given-names></name>
<name><surname>Powe</surname><given-names>D. G.</given-names></name>
<name><surname>Ahmed</surname><given-names>R. A.</given-names></name>
<name><surname>Collins</surname><given-names>H. M.</given-names></name>
<name><surname>Soria</surname><given-names>D.</given-names></name>
<name><surname>Garibaldi</surname><given-names>J. M.</given-names></name>
<name><surname>Paish</surname><given-names>C. E.</given-names></name>
<name><surname>Ammar</surname><given-names>A. A.</given-names></name>
<name><surname>Grainge</surname><given-names>M. J.</given-names></name>
<name><surname>Ball</surname><given-names>G. R.</given-names></name>
<name><surname>Abdelghany</surname><given-names>M. K.</given-names></name>
<name><surname>Martinez-Pomares</surname><given-names>L.</given-names></name>
<name><surname>Heery</surname><given-names>D. M.</given-names></name>
<name><surname>Ellis</surname><given-names>I. O.</given-names></name>
</person-group><year>2009</year><article-title>Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome</article-title><source>Cancer Res.</source><volume>69</volume><fpage>3802</fpage><lpage>3809</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3907</pub-id><pub-id pub-id-type="pmid">19366799</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>D. A.</given-names></name>
<name><surname>Kivimae</surname><given-names>S.</given-names></name>
<name><surname>Hoshino</surname><given-names>J.</given-names></name>
<name><surname>Suriben</surname><given-names>R.</given-names></name>
<name><surname>Martin</surname><given-names>P. M.</given-names></name>
<name><surname>Baxter</surname><given-names>N.</given-names></name>
<name><surname>Cheyette</surname><given-names>B. N.</given-names></name>
</person-group><year>2006</year><article-title>Three Dact gene family members are expressed during embryonic development and in the adult brains of mice</article-title><source>Dev. Dyn.</source><volume>235</volume><fpage>2620</fpage><lpage>2630</lpage><pub-id pub-id-type="doi">10.1002/dvdy.20917</pub-id><pub-id pub-id-type="pmid">16881060</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fraga</surname><given-names>M. F.</given-names></name>
<name><surname>Ballestar</surname><given-names>E.</given-names></name>
<name><surname>Villar-Garea</surname><given-names>A.</given-names></name>
<name><surname>Boix-Chornet</surname><given-names>M.</given-names></name>
<name><surname>Espada</surname><given-names>J.</given-names></name>
<name><surname>Schotta</surname><given-names>G.</given-names></name>
<name><surname>Bonaldi</surname><given-names>T.</given-names></name>
<name><surname>Haydon</surname><given-names>C.</given-names></name>
<name><surname>Ropero</surname><given-names>S.</given-names></name>
<name><surname>Petrie</surname><given-names>K.</given-names></name>
<name><surname>Iyer</surname><given-names>N. G.</given-names></name>
<name><surname>Perez-Rosado</surname><given-names>A.</given-names></name>
<name><surname>Calvo</surname><given-names>E.</given-names></name>
<name><surname>Lopez</surname><given-names>J. A.</given-names></name>
<name><surname>Cano</surname><given-names>A.</given-names></name>
<name><surname>Calasanz</surname><given-names>M. J.</given-names></name>
<name><surname>Colomer</surname><given-names>D.</given-names></name>
<name><surname>Piris</surname><given-names>M. A.</given-names></name>
<name><surname>Ahn</surname><given-names>N.</given-names></name>
<name><surname>Imhof</surname><given-names>A.</given-names></name>
<name><surname>Caldas</surname><given-names>C.</given-names></name>
<name><surname>Jenuwein</surname><given-names>T.</given-names></name>
<name><surname>Esteller</surname><given-names>M.</given-names></name>
</person-group><year>2005</year><article-title>Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer</article-title><source>Nat. Genet.</source><volume>37</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/ng1531</pub-id><pub-id pub-id-type="pmid">15765097</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gabay</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Felsher</surname><given-names>D. W.</given-names></name>
</person-group><year>2014</year><article-title>MYC activation is a hallmark of cancer initiation and maintenance</article-title><source>Cold Spring Harb. Perspect. Med.</source><volume>4</volume><elocation-id>a014241</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a014241</pub-id><!--<pub-id pub-id-type="pmcid">PMC4031954</pub-id>--><pub-id pub-id-type="pmid">24890832</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giuliani</surname><given-names>N.</given-names></name>
<name><surname>Accardi</surname><given-names>F.</given-names></name>
<name><surname>Marchica</surname><given-names>V.</given-names></name>
<name><surname>Dalla Palma</surname><given-names>B.</given-names></name>
<name><surname>Storti</surname><given-names>P.</given-names></name>
<name><surname>Toscani</surname><given-names>D.</given-names></name>
<name><surname>Vicario</surname><given-names>E.</given-names></name>
<name><surname>Malavasi</surname><given-names>F.</given-names></name>
</person-group><year>2019</year><article-title>Novel targets for the treatment of relapsing multiple myeloma</article-title><source>Expert Rev. Hematol.</source><volume>12</volume><fpage>481</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1080/17474086.2019.1624158</pub-id><pub-id pub-id-type="pmid">31125526</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gong</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Jing</surname><given-names>Y.</given-names></name>
</person-group><year>2019</year><article-title>Apoptosis induction byHistone deacetylase inhibitors in cancer cells: role of Ku70</article-title><source>Int. J. Mol. Sci.</source><volume>20</volume><fpage>1601</fpage><pub-id pub-id-type="doi">10.3390/ijms20071601</pub-id><!--<pub-id pub-id-type="pmcid">PMC6480544</pub-id>--><pub-id pub-id-type="pmid">30935057</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>G.</given-names></name>
<name><surname>Kang</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Tan</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>J. L.</given-names></name>
</person-group><year>2014</year><article-title>High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene</article-title><source>FEBS Lett.</source><volume>588</volume><fpage>1780</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2014.03.038</pub-id><pub-id pub-id-type="pmid">24685695</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>L.</given-names></name>
<name><surname>Torres-Lockhart</surname><given-names>K.</given-names></name>
<name><surname>Forster</surname><given-names>N.</given-names></name>
<name><surname>Ramakrishnan</surname><given-names>S.</given-names></name>
<name><surname>Greninger</surname><given-names>P.</given-names></name>
<name><surname>Garnett</surname><given-names>M. J.</given-names></name>
<name><surname>McDermott</surname><given-names>U.</given-names></name>
<name><surname>Rothenberg</surname><given-names>S. M.</given-names></name>
<name><surname>Benes</surname><given-names>C. H.</given-names></name>
<name><surname>Ellisen</surname><given-names>L. W.</given-names></name>
</person-group><year>2013</year><article-title>Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma</article-title><source>Cancer Discov.</source><volume>3</volume><fpage>324</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0417</pub-id><!--<pub-id pub-id-type="pmcid">PMC3595349</pub-id>--><pub-id pub-id-type="pmid">23274910</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Howes</surname><given-names>S. C.</given-names></name>
<name><surname>Alushin</surname><given-names>G. M.</given-names></name>
<name><surname>Shida</surname><given-names>T.</given-names></name>
<name><surname>Nachury</surname><given-names>M. V.</given-names></name>
<name><surname>Nogales</surname><given-names>E.</given-names></name>
</person-group><year>2014</year><article-title>Effects of tubulin acetylation and tubulin acetyltransferase binding on microtubule structure</article-title><source>Mol. Biol. Cell</source><volume>25</volume><fpage>257</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1091/mbc.e13-07-0387</pub-id><!--<pub-id pub-id-type="pmcid">PMC3890346</pub-id>--><pub-id pub-id-type="pmid">24227885</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hua</surname><given-names>H.</given-names></name>
<name><surname>Kong</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Luo</surname><given-names>T.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
</person-group><year>2019</year><article-title>Targeting mTOR for cancer therapy</article-title><source>J. Hematol. Oncol.</source><volume>12</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/s13045-019-0754-1</pub-id><!--<pub-id pub-id-type="pmcid">PMC6612215</pub-id>--><pub-id pub-id-type="doaj">b2f26c6c535c4e95a373b46bd7052153</pub-id><pub-id pub-id-type="pmid">31277692</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Imai</surname><given-names>Y.</given-names></name>
<name><surname>Hirano</surname><given-names>M.</given-names></name>
<name><surname>Kobayashi</surname><given-names>M.</given-names></name>
<name><surname>Futami</surname><given-names>M.</given-names></name>
<name><surname>Tojo</surname><given-names>A.</given-names></name>
</person-group><year>2019</year><article-title>HDAC inhibitors exert anti-myeloma effects through multiple modes of action</article-title><source>Cancers (Basel)</source><volume>11</volume><fpage>475</fpage><pub-id pub-id-type="doi">10.3390/cancers11040475</pub-id><!--<pub-id pub-id-type="pmcid">PMC6520917</pub-id>--><pub-id pub-id-type="pmid">30987296</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janke</surname><given-names>C.</given-names></name>
<name><surname>Bulinski</surname><given-names>J. C.</given-names></name>
</person-group><year>2011</year><article-title>Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>12</volume><fpage>773</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1038/nrm3227</pub-id><pub-id pub-id-type="pmid">22086369</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>Tan</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Kivimae</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Zhuang</surname><given-names>L.</given-names></name>
<name><surname>Lee</surname><given-names>P. L.</given-names></name>
<name><surname>Chan</surname><given-names>M. T.</given-names></name>
<name><surname>Stanton</surname><given-names>L. W.</given-names></name>
<name><surname>Liu</surname><given-names>E. T.</given-names></name>
<name><surname>Cheyette</surname><given-names>B. N.</given-names></name>
<name><surname>Yu</surname><given-names>Q.</given-names></name>
</person-group><year>2008</year><article-title>DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications</article-title><source>Cancer Cell</source><volume>13</volume><fpage>529</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.04.019</pub-id><!--<pub-id pub-id-type="pmcid">PMC2577847</pub-id>--><pub-id pub-id-type="pmid">18538736</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kao</surname><given-names>J. T.</given-names></name>
<name><surname>Chuah</surname><given-names>S. K.</given-names></name>
<name><surname>Huang</surname><given-names>C. C.</given-names></name>
<name><surname>Chen</surname><given-names>C. L.</given-names></name>
<name><surname>Wang</surname><given-names>C. C.</given-names></name>
<name><surname>Hung</surname><given-names>C. H.</given-names></name>
<name><surname>Chen</surname><given-names>C. H.</given-names></name>
<name><surname>Wang</surname><given-names>J. H.</given-names></name>
<name><surname>Lu</surname><given-names>S. N.</given-names></name>
<name><surname>Lee</surname><given-names>C. M.</given-names></name>
<name><surname>Changchien</surname><given-names>C. S.</given-names></name>
<name><surname>Hu</surname><given-names>T. H.</given-names></name>
</person-group><year>2007</year><article-title>P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection</article-title><source>Liver Int.</source><volume>27</volume><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2007.01499.x</pub-id><pub-id pub-id-type="pmid">17617120</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>P. N.</given-names></name>
<name><surname>Grabow</surname><given-names>S.</given-names></name>
<name><surname>Delbridge</surname><given-names>A. R.</given-names></name>
<name><surname>Strasser</surname><given-names>A.</given-names></name>
<name><surname>Adams</surname><given-names>J. M.</given-names></name>
</person-group><year>2011</year><article-title>Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice</article-title><source>Blood</source><volume>118</volume><fpage>6380</fpage><lpage>6386</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-07-367672</pub-id><!--<pub-id pub-id-type="pmcid">PMC3236120</pub-id>--><pub-id pub-id-type="pmid">21998213</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H. J.</given-names></name>
<name><surname>Bae</surname><given-names>S. C.</given-names></name>
</person-group><year>2011</year><article-title>Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs</article-title><source>Am. J. Transl. Res.</source><volume>3</volume><fpage>166</fpage><lpage>179</lpage><!--<pub-id pub-id-type="pmcid">PMC3056563</pub-id>--><pub-id pub-id-type="pmid">21416059</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S. J.</given-names></name>
<name><surname>Kim</surname><given-names>U. J.</given-names></name>
<name><surname>Yoo</surname><given-names>H. Y.</given-names></name>
<name><surname>Choi</surname><given-names>Y. J.</given-names></name>
<name><surname>Kang</surname><given-names>K. W.</given-names></name>
</person-group><year>2020</year><article-title>Anti-cancer effects of CKD-581, a potent histone deacetylase inhibitor against diffuse large B-cell lymphoma</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><fpage>4377</fpage><pub-id pub-id-type="doi">10.3390/ijms21124377</pub-id><!--<pub-id pub-id-type="pmcid">PMC7352247</pub-id>--><pub-id pub-id-type="doaj">2c866506cdc143d58a8762de96824724</pub-id><pub-id pub-id-type="pmid">32575557</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y.</given-names></name>
<name><surname>Reifenberger</surname><given-names>G.</given-names></name>
<name><surname>Lu</surname><given-names>D.</given-names></name>
<name><surname>Endo</surname><given-names>T.</given-names></name>
<name><surname>Carson</surname><given-names>D. A.</given-names></name>
<name><surname>Gast</surname><given-names>S. M.</given-names></name>
<name><surname>Meschenmoser</surname><given-names>K.</given-names></name>
<name><surname>Nowak</surname><given-names>M.</given-names></name>
<name><surname>Schmidt-Wolf</surname><given-names>I. G.</given-names></name>
</person-group><year>2011</year><article-title>Influencing the Wnt signaling pathway in multiple myeloma</article-title><source>Anticancer Res.</source><volume>31</volume><fpage>725</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">21378363</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwak</surname><given-names>B.</given-names></name>
<name><surname>Kim</surname><given-names>D. U.</given-names></name>
<name><surname>Kim</surname><given-names>T. O.</given-names></name>
<name><surname>Kim</surname><given-names>H. S.</given-names></name>
<name><surname>Kim</surname><given-names>S. W.</given-names></name>
</person-group><year>2018</year><article-title>MicroRNA-552 links Wnt signaling to p53 tumor suppressor in colorectal cancer</article-title><source>Int. J. Oncol.</source><volume>53</volume><fpage>1800</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.3892/ijo.2018.4505</pub-id><pub-id pub-id-type="pmid">30066856</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leal</surname><given-names>P.</given-names></name>
<name><surname>Garcia</surname><given-names>P.</given-names></name>
<name><surname>Sandoval</surname><given-names>A.</given-names></name>
<name><surname>Buchegger</surname><given-names>K.</given-names></name>
<name><surname>Weber</surname><given-names>H.</given-names></name>
<name><surname>Tapia</surname><given-names>O.</given-names></name>
<name><surname>Roa</surname><given-names>J. C.</given-names></name>
</person-group><year>2013</year><article-title>AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines</article-title><source>Onco Targets Ther.</source><volume>6</volume><fpage>1373</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.2147/OTT.S46897</pub-id><!--<pub-id pub-id-type="pmcid">PMC3794848</pub-id>--><pub-id pub-id-type="pmid">24124380</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Seto</surname><given-names>E.</given-names></name>
</person-group><year>2016</year><article-title>HDACs and HDAC inhibitors in cancer development and therapy</article-title><source>Cold Spring Harb. Perspect. Med.</source><volume>6</volume><elocation-id>a026831</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a026831</pub-id><!--<pub-id pub-id-type="pmcid">PMC5046688</pub-id>--><pub-id pub-id-type="pmid">27599530</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mandal</surname><given-names>A.</given-names></name>
<name><surname>Waxman</surname><given-names>J.</given-names></name>
</person-group><year>2014</year><article-title>Retinoic acid negatively regulates dact3b expression in the hindbrain of zebrafish embryos</article-title><source>Gene Expr. Patterns</source><volume>16</volume><fpage>122</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.gep.2014.09.003</pub-id><!--<pub-id pub-id-type="pmcid">PMC4254272</pub-id>--><pub-id pub-id-type="pmid">25266145</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Min</surname><given-names>C. K.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Kim</surname><given-names>S. J.</given-names></name>
<name><surname>Yoon</surname><given-names>D. H.</given-names></name>
<name><surname>Park</surname><given-names>S.-S.</given-names></name>
<name><surname>Han</surname><given-names>S.</given-names></name>
</person-group><year>2019</year><article-title>A phase 1, open-label, multi-center study of alteminostat (CKD-581) in combination with lenalidomide and dexamethasone in patients with previously treated multiple myeloma (MM)</article-title><source>Blood</source><volume>134</volume><fpage>1847</fpage><pub-id pub-id-type="doi">10.1182/blood-2019-127643</pub-id><pub-id pub-id-type="pmid">31578203</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mithraprabhu</surname><given-names>S.</given-names></name>
<name><surname>Kalff</surname><given-names>A.</given-names></name>
<name><surname>Chow</surname><given-names>A.</given-names></name>
<name><surname>Khong</surname><given-names>T.</given-names></name>
<name><surname>Spencer</surname><given-names>A.</given-names></name>
</person-group><year>2014</year><article-title>Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma</article-title><source>Epigenetics</source><volume>9</volume><fpage>1511</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.4161/15592294.2014.983367</pub-id><!--<pub-id pub-id-type="pmcid">PMC4622977</pub-id>--><pub-id pub-id-type="pmid">25482492</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mithraprabhu</surname><given-names>S.</given-names></name>
<name><surname>Khong</surname><given-names>T.</given-names></name>
<name><surname>Jones</surname><given-names>S. S.</given-names></name>
<name><surname>Spencer</surname><given-names>A.</given-names></name>
</person-group><year>2013</year><article-title>Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC</article-title><source>Br. J. Haematol.</source><volume>162</volume><fpage>559</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1111/bjh.12388</pub-id><pub-id pub-id-type="pmid">23692150</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morin</surname><given-names>P. J.</given-names></name>
<name><surname>Sparks</surname><given-names>A. B.</given-names></name>
<name><surname>Korinek</surname><given-names>V.</given-names></name>
<name><surname>Barker</surname><given-names>N.</given-names></name>
<name><surname>Clevers</surname><given-names>H.</given-names></name>
<name><surname>Vogelstein</surname><given-names>B.</given-names></name>
<name><surname>Kinzler</surname><given-names>K. W.</given-names></name>
</person-group><year>1997</year><article-title>Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC</article-title><source>Science</source><volume>275</volume><fpage>1787</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1126/science.275.5307.1787</pub-id><pub-id pub-id-type="pmid">9065402</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munemitsu</surname><given-names>S.</given-names></name>
<name><surname>Albert</surname><given-names>I.</given-names></name>
<name><surname>Souza</surname><given-names>B.</given-names></name>
<name><surname>Rubinfeld</surname><given-names>B.</given-names></name>
<name><surname>Polakis</surname><given-names>P.</given-names></name>
</person-group><year>1995</year><article-title>Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>92</volume><fpage>3046</fpage><lpage>3050</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.7.3046</pub-id><!--<pub-id pub-id-type="pmcid">PMC42356</pub-id>--><pub-id pub-id-type="pmid">7708772</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Musgrove</surname><given-names>E. A.</given-names></name>
<name><surname>Caldon</surname><given-names>C. E.</given-names></name>
<name><surname>Barraclough</surname><given-names>J.</given-names></name>
<name><surname>Stone</surname><given-names>A.</given-names></name>
<name><surname>Sutherland</surname><given-names>R. L.</given-names></name>
</person-group><year>2011</year><article-title>Cyclin D as a therapeutic target in cancer</article-title><source>Nat. Rev. Cancer</source><volume>11</volume><fpage>558</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/nrc3090</pub-id><pub-id pub-id-type="pmid">21734724</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nebbioso</surname><given-names>A.</given-names></name>
<name><surname>Carafa</surname><given-names>V.</given-names></name>
<name><surname>Conte</surname><given-names>M.</given-names></name>
<name><surname>Tambaro</surname><given-names>F. P.</given-names></name>
<name><surname>Abbondanza</surname><given-names>C.</given-names></name>
<name><surname>Martens</surname><given-names>J.</given-names></name>
<name><surname>Nees</surname><given-names>M.</given-names></name>
<name><surname>Benedetti</surname><given-names>R.</given-names></name>
<name><surname>Pallavicini</surname><given-names>I.</given-names></name>
<name><surname>Minucci</surname><given-names>S.</given-names></name>
<name><surname>Garcia-Manero</surname><given-names>G.</given-names></name>
<name><surname>Iovino</surname><given-names>F.</given-names></name>
<name><surname>Lania</surname><given-names>G.</given-names></name>
<name><surname>Ingenito</surname><given-names>C.</given-names></name>
<name><surname>Belsito Petrizzi</surname><given-names>V.</given-names></name>
<name><surname>Stunnenberg</surname><given-names>H. G.</given-names></name>
<name><surname>Altucci</surname><given-names>L.</given-names></name>
</person-group><year>2017</year><article-title>c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer</article-title><source>Clin. Cancer Res.</source><volume>23</volume><fpage>2542</fpage><lpage>2555</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2388</pub-id><pub-id pub-id-type="pmid">27358484</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qie</surname><given-names>S.</given-names></name>
<name><surname>Diehl</surname><given-names>J. A.</given-names></name>
</person-group><year>2016</year><article-title>Cyclin D1, cancer progression, and opportunities in cancer treatment</article-title><source>J. Mol. Med.</source><volume>94</volume><fpage>1313</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1007/s00109-016-1475-3</pub-id><!--<pub-id pub-id-type="pmcid">PMC5145738</pub-id>--><pub-id pub-id-type="pmid">27695879</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajkumar</surname><given-names>S. V.</given-names></name>
<name><surname>Dimopoulos</surname><given-names>M. A.</given-names></name>
<name><surname>Palumbo</surname><given-names>A.</given-names></name>
<name><surname>Blade</surname><given-names>J.</given-names></name>
<name><surname>Merlini</surname><given-names>G.</given-names></name>
<name><surname>Mateos</surname><given-names>M. V.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Hillengass</surname><given-names>J.</given-names></name>
<name><surname>Kastritis</surname><given-names>E.</given-names></name>
<name><surname>Richardson</surname><given-names>P.</given-names></name>
<name><surname>Landgren</surname><given-names>O.</given-names></name>
<name><surname>Paiva</surname><given-names>B.</given-names></name>
<name><surname>Dispenzieri</surname><given-names>A.</given-names></name>
<name><surname>Weiss</surname><given-names>B.</given-names></name>
<name><surname>LeLeu</surname><given-names>X.</given-names></name>
<name><surname>Zweegman</surname><given-names>S.</given-names></name>
<name><surname>Lonial</surname><given-names>S.</given-names></name>
<name><surname>Rosinol</surname><given-names>L.</given-names></name>
<name><surname>Zamagni</surname><given-names>E.</given-names></name>
<name><surname>Jagannath</surname><given-names>S.</given-names></name>
<name><surname>Sezer</surname><given-names>O.</given-names></name>
<name><surname>Kristinsson</surname><given-names>S. Y.</given-names></name>
<name><surname>Caers</surname><given-names>J.</given-names></name>
<name><surname>Usmani</surname><given-names>S. Z.</given-names></name>
<name><surname>Lahuerta</surname><given-names>J. J.</given-names></name>
<name><surname>Johnsen</surname><given-names>H. E.</given-names></name>
<name><surname>Beksac</surname><given-names>M.</given-names></name>
<name><surname>Cavo</surname><given-names>M.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>H.</given-names></name>
<name><surname>Terpos</surname><given-names>E.</given-names></name>
<name><surname>Kyle</surname><given-names>R. A.</given-names></name>
<name><surname>Anderson</surname><given-names>K. C.</given-names></name>
<name><surname>Durie</surname><given-names>B. G.</given-names></name>
<name><surname>Miguel</surname><given-names>J. F.</given-names></name>
</person-group><year>2014</year><article-title>International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma</article-title><source>Lancet Oncol.</source><volume>15</volume><fpage>e538</fpage><lpage>e548</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70442-5</pub-id><pub-id pub-id-type="pmid">25439696</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramakrishnan</surname><given-names>V. G.</given-names></name>
<name><surname>Miller</surname><given-names>K. C.</given-names></name>
<name><surname>Macon</surname><given-names>E. P.</given-names></name>
<name><surname>Kimlinger</surname><given-names>T. K.</given-names></name>
<name><surname>Haug</surname><given-names>J.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Gonsalves</surname><given-names>W. I.</given-names></name>
<name><surname>Rajkumar</surname><given-names>S. V.</given-names></name>
<name><surname>Kumar</surname><given-names>S. K.</given-names></name>
</person-group><year>2019</year><article-title>Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma</article-title><source>Haematologica</source><volume>104</volume><fpage>2061</fpage><lpage>2074</lpage><pub-id pub-id-type="doi">10.3324/haematol.2018.211110</pub-id><!--<pub-id pub-id-type="pmcid">PMC6886422</pub-id>--><pub-id pub-id-type="pmid">30846494</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Liang</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Pan</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
</person-group><year>2017</year><article-title>MiRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3</article-title><source>Cancer Lett.</source><volume>390</volume><fpage>126</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2017.01.009</pub-id><pub-id pub-id-type="pmid">28108314</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rennoll</surname><given-names>S.</given-names></name>
<name><surname>Yochum</surname><given-names>G.</given-names></name>
</person-group><year>2015</year><article-title>Regulation of MYC gene expression by aberrant Wnt/beta-catenin signaling in colorectal cancer</article-title><source>World J. Biol. Chem.</source><volume>6</volume><fpage>290</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.4331/wjbc.v6.i4.290</pub-id><!--<pub-id pub-id-type="pmcid">PMC4657124</pub-id>--><pub-id pub-id-type="pmid">26629312</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riascos-Bernal</surname><given-names>D. F.</given-names></name>
<name><surname>Chinnasamy</surname><given-names>P.</given-names></name>
<name><surname>Cao</surname><given-names>L. L.</given-names></name>
<name><surname>Dunaway</surname><given-names>C. M.</given-names></name>
<name><surname>Valenta</surname><given-names>T.</given-names></name>
<name><surname>Basler</surname><given-names>K.</given-names></name>
<name><surname>Sibinga</surname><given-names>N. E.</given-names></name>
</person-group><year>2016</year><article-title>beta-Catenin C-terminal signals suppress p53 and are essential for artery formation</article-title><source>Nat. Commun.</source><volume>7</volume><fpage>12389</fpage><pub-id pub-id-type="doi">10.1038/ncomms12389</pub-id><!--<pub-id pub-id-type="pmcid">PMC4979065</pub-id>--><pub-id pub-id-type="doaj">714f114658344539a951b80874578064</pub-id><pub-id pub-id-type="pmid">27499244</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanchez</surname><given-names>E.</given-names></name>
<name><surname>Shen</surname><given-names>J.</given-names></name>
<name><surname>Steinberg</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Bonavida</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Z.-W.</given-names></name>
<name><surname>Berenson</surname><given-names>J. R.</given-names></name>
</person-group><year>2011</year><article-title>The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Leuk. Res.</source><volume>35</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2010.06.026</pub-id><pub-id pub-id-type="pmid">20650529</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saukkonen</surname><given-names>K.</given-names></name>
<name><surname>Hagstrom</surname><given-names>J.</given-names></name>
<name><surname>Mustonen</surname><given-names>H.</given-names></name>
<name><surname>Juuti</surname><given-names>A.</given-names></name>
<name><surname>Nordling</surname><given-names>S.</given-names></name>
<name><surname>Kallio</surname><given-names>P.</given-names></name>
<name><surname>Alitalo</surname><given-names>K.</given-names></name>
<name><surname>Seppanen</surname><given-names>H.</given-names></name>
<name><surname>Haglund</surname><given-names>C.</given-names></name>
</person-group><year>2016</year><article-title>PROX1 and beta-catenin are prognostic markers in pancreatic ductal adenocarcinoma</article-title><source>BMC Cancer</source><volume>16</volume><fpage>472</fpage><pub-id pub-id-type="doi">10.1186/s12885-016-2497-5</pub-id><!--<pub-id pub-id-type="pmcid">PMC4944261</pub-id>--><pub-id pub-id-type="pmid">27411302</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shao</surname><given-names>N.</given-names></name>
<name><surname>Zou</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Qu</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>D.</given-names></name>
<name><surname>Ji</surname><given-names>C.</given-names></name>
</person-group><year>2012</year><article-title>Hyper-activation of WNT/beta-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia</article-title><source>Leuk. Lymphoma</source><volume>53</volume><fpage>1769</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.3109/10428194.2012.663085</pub-id><pub-id pub-id-type="pmid">22303878</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shieh</surname><given-names>J. M.</given-names></name>
<name><surname>Tang</surname><given-names>Y. A.</given-names></name>
<name><surname>Hu</surname><given-names>F. H.</given-names></name>
<name><surname>Huang</surname><given-names>W. J.</given-names></name>
<name><surname>Wang</surname><given-names>Y. J.</given-names></name>
<name><surname>Jen</surname><given-names>J.</given-names></name>
<name><surname>Liao</surname><given-names>S. Y.</given-names></name>
<name><surname>Lu</surname><given-names>Y. H.</given-names></name>
<name><surname>Yeh</surname><given-names>Y. L.</given-names></name>
<name><surname>Wang</surname><given-names>T. W.</given-names></name>
<name><surname>Lin</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>Y. C.</given-names></name>
</person-group><year>2017</year><article-title>A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer</article-title><source>Int. J. Cancer</source><volume>140</volume><fpage>2375</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1002/ijc.30664</pub-id><pub-id pub-id-type="pmid">28233309</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>A. K.</given-names></name>
<name><surname>Bishayee</surname><given-names>A.</given-names></name>
<name><surname>Pandey</surname><given-names>A. K.</given-names></name>
</person-group><year>2018</year><article-title>Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy</article-title><source>Nutrients</source><volume>10</volume><fpage>731</fpage><pub-id pub-id-type="doi">10.3390/nu10060731</pub-id><!--<pub-id pub-id-type="pmcid">PMC6024317</pub-id>--><pub-id pub-id-type="pmid">29882797</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sivaraj</surname><given-names>D.</given-names></name>
<name><surname>Green</surname><given-names>M. M.</given-names></name>
<name><surname>Gasparetto</surname><given-names>C.</given-names></name>
</person-group><year>2017</year><article-title>Panobinostat for the management of multiple myeloma</article-title><source>Future Oncol.</source><volume>13</volume><fpage>477</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.2217/fon-2016-0329</pub-id><pub-id pub-id-type="pmid">27776419</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spaan</surname><given-names>I.</given-names></name>
<name><surname>Raymakers</surname><given-names>R. A.</given-names></name>
<name><surname>van de Stolpe</surname><given-names>A.</given-names></name>
<name><surname>Peperzak</surname><given-names>V.</given-names></name>
</person-group><year>2018</year><article-title>Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential</article-title><source>J. Hematol. Oncol.</source><volume>11</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/s13045-018-0615-3</pub-id><!--<pub-id pub-id-type="pmcid">PMC5960217</pub-id>--><pub-id pub-id-type="pmid">29776381</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><year>2016</year><article-title>Role of Wnt/beta-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells</article-title><source>Oncol. Lett.</source><volume>12</volume><fpage>4623</fpage><lpage>4629</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.5289</pub-id><!--<pub-id pub-id-type="pmcid">PMC5228543</pub-id>--><pub-id pub-id-type="pmid">28105169</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>VanArsdale</surname><given-names>T.</given-names></name>
<name><surname>Boshoff</surname><given-names>C.</given-names></name>
<name><surname>Arndt</surname><given-names>K. T.</given-names></name>
<name><surname>Abraham</surname><given-names>R. T.</given-names></name>
</person-group><year>2015</year><article-title>Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment</article-title><source>Clin. Cancer Res.</source><volume>21</volume><fpage>2905</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0816</pub-id><pub-id pub-id-type="pmid">25941111</pub-id></element-citation></ref><ref id="ref55"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vousden</surname><given-names>K. H.</given-names></name>
</person-group><year>2000</year><article-title>p53: death star</article-title><source>Cell</source><volume>103</volume><fpage>691</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00171-9</pub-id><pub-id pub-id-type="pmid">11114324</pub-id></element-citation></ref><ref id="ref56"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y. X.</given-names></name>
<name><surname>Zhang</surname><given-names>J. H.</given-names></name>
<name><surname>Gu</surname><given-names>Z. W.</given-names></name>
</person-group><year>2009</year><article-title>Wnt/beta-catenin signal pathway and malignant hematological disease -- review</article-title><source>Zhongguo Shi Yan Xue Ye Xue Za Zhi</source><volume>17</volume><fpage>234</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">19236787</pub-id></element-citation></ref><ref id="ref57"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wattanathamsan</surname><given-names>O.</given-names></name>
<name><surname>Thararattanobon</surname><given-names>R.</given-names></name>
<name><surname>Rodsiri</surname><given-names>R.</given-names></name>
<name><surname>Chanvorachote</surname><given-names>P.</given-names></name>
<name><surname>Vinayanuwattikun</surname><given-names>C.</given-names></name>
<name><surname>Pongrakhananon</surname><given-names>V.</given-names></name>
</person-group><year>2021</year><article-title>Tubulin acetylation enhances lung cancer resistance to paclitaxel-induced cell death through Mcl-1 stabilization</article-title><source>Cell Death Discov.</source><volume>7</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1038/s41420-021-00453-9</pub-id><!--<pub-id pub-id-type="pmcid">PMC8024319</pub-id>--><pub-id pub-id-type="doaj">48077c0dc21e4bcbaf7f8ffd8d001e3c</pub-id><pub-id pub-id-type="pmid">33824297</pub-id></element-citation></ref><ref id="ref58"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weichert</surname><given-names>W.</given-names></name>
<name><surname>Denkert</surname><given-names>C.</given-names></name>
<name><surname>Noske</surname><given-names>A.</given-names></name>
<name><surname>Darb-Esfahani</surname><given-names>S.</given-names></name>
<name><surname>Dietel</surname><given-names>M.</given-names></name>
<name><surname>Kalloger</surname><given-names>S. E.</given-names></name>
<name><surname>Huntsman</surname><given-names>D. G.</given-names></name>
<name><surname>Kobel</surname><given-names>M.</given-names></name>
</person-group><year>2008a</year><article-title>Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas</article-title><source>Neoplasia</source><volume>10</volume><fpage>1021</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1593/neo.08474</pub-id><!--<pub-id pub-id-type="pmcid">PMC2517648</pub-id>--><pub-id pub-id-type="pmid">18714364</pub-id></element-citation></ref><ref id="ref59"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weichert</surname><given-names>W.</given-names></name>
<name><surname>Roske</surname><given-names>A.</given-names></name>
<name><surname>Gekeler</surname><given-names>V.</given-names></name>
<name><surname>Beckers</surname><given-names>T.</given-names></name>
<name><surname>Ebert</surname><given-names>M. P.</given-names></name>
<name><surname>Pross</surname><given-names>M.</given-names></name>
<name><surname>Dietel</surname><given-names>M.</given-names></name>
<name><surname>Denkert</surname><given-names>C.</given-names></name>
<name><surname>Rocken</surname><given-names>C.</given-names></name>
</person-group><year>2008b</year><article-title>Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis</article-title><source>Lancet Oncol.</source><volume>9</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70004-4</pub-id><pub-id pub-id-type="pmid">18207460</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xi</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Tao</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Shan</surname><given-names>J.</given-names></name>
<name><surname>Inchauste</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Mercedes</surname><given-names>L.</given-names></name>
<name><surname>Hong</surname><given-names>J. A.</given-names></name>
<name><surname>Rao</surname><given-names>M.</given-names></name>
<name><surname>Schrump</surname><given-names>D. S.</given-names></name>
</person-group><year>2010</year><article-title>Cigarette smoke induces C/EBP-beta-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells</article-title><source>PLoS ONE</source><volume>5</volume><elocation-id>e13764</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013764</pub-id><!--<pub-id pub-id-type="pmcid">PMC2966442</pub-id>--><pub-id pub-id-type="pmid">21048943</pub-id></element-citation></ref><ref id="ref61"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xi</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
</person-group><year>2014</year><article-title>Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis</article-title><source>Cancer Lett.</source><volume>353</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2014.07.010</pub-id><pub-id pub-id-type="pmid">25042867</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>C. Y.</given-names></name>
<name><surname>Bai</surname><given-names>L.</given-names></name>
</person-group><year>2018</year><article-title>MCL-1 inhibition in cancer treatment</article-title><source>Onco Targets Ther.</source><volume>11</volume><fpage>7301</fpage><lpage>7314</lpage><pub-id pub-id-type="doi">10.2147/OTT.S146228</pub-id><!--<pub-id pub-id-type="pmcid">PMC6205821</pub-id>--><pub-id pub-id-type="pmid">30425521</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>T.</given-names></name>
<name><surname>Choi</surname><given-names>Y.</given-names></name>
<name><surname>Joh</surname><given-names>J. W.</given-names></name>
<name><surname>Cho</surname><given-names>S. K.</given-names></name>
<name><surname>Kim</surname><given-names>D. S.</given-names></name>
<name><surname>Park</surname><given-names>S. G.</given-names></name>
</person-group><year>2019</year><article-title>Phosphorylation of p53 serine 15 is a predictor of survival for patients with hepatocellular carcinoma</article-title><source>Can. J. Gastroenterol. Hepatol.</source><volume>2019</volume><elocation-id>9015453</elocation-id><pub-id pub-id-type="doi">10.1155/2019/9015453</pub-id><!--<pub-id pub-id-type="pmcid">PMC6383407</pub-id>--><pub-id pub-id-type="pmid">30881947</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>S.</given-names></name>
<name><surname>Tao</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>D.</given-names></name>
</person-group><year>2020</year><article-title>Role of Wnt/beta-catenin signaling in the chemoresistance modulation of colorectal cancer</article-title><source>Biomed. Res. Int.</source><volume>2020</volume><elocation-id>9390878</elocation-id><pub-id pub-id-type="doi">10.1155/2020/9390878</pub-id><!--<pub-id pub-id-type="pmcid">PMC7109575</pub-id>--><pub-id pub-id-type="pmid">32258160</pub-id></element-citation></ref><ref id="ref65"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>X. G.</given-names></name>
<name><surname>Huang</surname><given-names>Y. R.</given-names></name>
<name><surname>Yu</surname><given-names>T.</given-names></name>
<name><surname>Jiang</surname><given-names>H. W.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>X. Y.</given-names></name>
</person-group><year>2019</year><article-title>Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner</article-title><source>Oncol. Lett.</source><volume>18</volume><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.3892/ol.2019.10301</pub-id><!--<pub-id pub-id-type="pmcid">PMC6540238</pub-id>--><pub-id pub-id-type="pmid">31289512</pub-id></element-citation></ref><ref id="ref66"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>R.</given-names></name>
<name><surname>Du</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>X.</given-names></name>
<name><surname>Jiao</surname><given-names>X.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
</person-group><year>2015</year><article-title>Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling</article-title><source>PLoS ONE</source><volume>10</volume><elocation-id>e0136193</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0136193</pub-id><!--<pub-id pub-id-type="pmcid">PMC4542213</pub-id>--><pub-id pub-id-type="pmid">26287365</pub-id></element-citation></ref><ref id="ref67"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Ling</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>E.</given-names></name>
<name><surname>Wu</surname><given-names>G.</given-names></name>
</person-group><year>2017</year><article-title>Dact3 inhibits the malignant phenotype of non-small cell lung cancer through downregulation of c-Myb</article-title><source>Int. J. Clin. Exp. Pathol.</source><volume>10</volume><fpage>11580</fpage><lpage>11587</lpage><!--<pub-id pub-id-type="pmcid">PMC6966047</pub-id>--><pub-id pub-id-type="pmid">31966514</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Fig. 1</label><caption><p>CKD-581 increases acetylated proteins and suppresses cell proliferation in hematologic cancer cells. (A) The chemical structure of CKD-581. (B) Acetylation of histone H3, H4 and tubulin. MM.1S cells were treated with 30-1000 nM CKD-581 or SAHA for 6 h. Acetylation of proteins was analyzed by immunoblottings. (C) Inhibitory effects of CKD-581 and SAHA on cell viabilities of hematologic cancer cell lines. All data represent mean &#x000b1; SEM of at least three independent experiments.</p></caption><graphic xlink:href="bt-30-5-435-f1" position="float"/></fig><fig position="float" id="F2"><label>Fig. 2</label><caption><p>CKD-581 down-regulates Wnt/&#x003b2;-catenin pathway. (A) Heatmap analysis of gene expression profiles in hematologic cancer cells. HH and MJ cells were treated with 100 nM CKD-581, and Total RNA samples were purified. Expression level of mRNA was analyzed with the Infinium<sup>&#x000ae;</sup> HumanHT-12 BeadChip. (B) Effects of HDAC inhibitors on DACT family expression. MM.1S and RPMI8226 cells were treated with the indicated concentrations of CKD-581 or SAHA for 24 h, and total cell lysates were subjected to immunoblottings. (C) DACT3 expression induced by CKD-581. MM.1S and RPMI8226 cells were treated with 300 nM CKD-581 in a time-dependent manner. (D) MM.1S and RPMI8226 cells were treated with various concentrations of CKD-581 or SAHA for 24 h. And total cell lysates were analyzed by immunoblottings for &#x003b2;-catenin and c-Myc. Data represent mean &#x000b1; SEM (significant vs. control; *<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01, ***<italic>p</italic>&#x0003c;0.001). C, control; S, 1000 nM SAHA.</p></caption><graphic xlink:href="bt-30-5-435-f2a" position="float"/><graphic xlink:href="bt-30-5-435-f2b" position="float"/></fig><fig position="float" id="F3"><label>Fig. 3</label><caption><p>CKD-581 decreases the expression of cell cycle related proteins and induces apoptosis in MM. (A, B) Effects of CKD-581 and SAHA on CDK4 and cyclin D1 expression. (A) 30-1000 nM CKD-581 or 30-3000 nM SAHA was treated on MM.1S cells for 24 h. (B) CKD-581 (30-1000 nM) or 1000 nM SAHA was treated on RPMI8226 for 24 h (left). RPMI8226 cells were treated with 300 nM CKD-581 according to time course (right). After treatment, total cell lysates were analyzed by immunoblotting for CDK4 and cyclin D1. (C) Flow-cytometry analysis. MM.1S and RPMI8226 cells were treated with CKD-581 for 24 h. And cell cycle populations were determined using flow-cytometry. (D) Cleaved caspase-3 was detected by immunoblotting. Data represent mean &#x000b1; SEM (significant vs. control; *<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01, ***<italic>p</italic>&#x0003c;0.001). C, control; S, 1000 nM SAHA.</p></caption><graphic xlink:href="bt-30-5-435-f3a" position="float"/><graphic xlink:href="bt-30-5-435-f3b" position="float"/></fig><fig position="float" id="F4"><label>Fig. 4</label><caption><p>CKD-581 activates tumor suppressors and reduces the expression of BCL-2 family in MM. (A) MM.1S and RPMI8226 cells were treated with 300 nM CKD-581 according to time course. And total cell lysates were subjected to immunoblottings for Ser<sup>15</sup>-phosphorylated p53, p53 and p21. (B) MM.1S and RPMI8226 cells were treated with CKD-581 or SAHA for 24 h. BCL-2 and BCL-xL were detected by immunoblottings. Data represent mean &#x000b1; SEM (significant vs. control; *<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01, ***<italic>p</italic>&#x0003c;0.001). C, control; S, 1000 nM SAHA.</p></caption><graphic xlink:href="bt-30-5-435-f4" position="float"/></fig><fig position="float" id="F5"><label>Fig. 5</label><caption><p>Tumor growth is delayed by CKD-581 in MM.1S xenograft model. (A) NOD.CB17 SCID mice were used for MM.1S (1&#x000d7;10<sup>6</sup> cells/mouse) implantation. After tumors reached to about 100 mm<sup>3</sup>, the mice were treated with vehicle or CKD-581 (40 and 60 mg/kg) two times a week. (B) Dot graph showed individual tumor size. (C) Body weight change. Data represent mean &#x000b1; SEM (significant vs. vehicle group; **<italic>p</italic>&#x0003c;0.01, ***<italic>p</italic>&#x0003c;0.001).</p></caption><graphic xlink:href="bt-30-5-435-f5" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Effects of CKD-581 on HDAC enzymes. HDAC enzyme activity was determined by fluorescence based-enzymatic assays</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" colspan="3" rowspan="1">HDAC enzyme assay IC<sup>50</sup> (nM)</th></tr></thead><tbody><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="4" colspan="1">Class I</td><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">HDAC1</td><td valign="top" align="center" rowspan="1" colspan="1">0.50 &#x000b1; 0.11</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">HDAC2</td><td valign="top" align="center" rowspan="1" colspan="1">2.22 &#x000b1; 0.39</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">HDAC3</td><td valign="top" align="center" rowspan="1" colspan="1">0.61 &#x000b1; 0.09</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">HDAC8</td><td valign="top" align="center" rowspan="1" colspan="1">49.82 &#x000b1; 18.24</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="3" colspan="1">Class IIa</td><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">HDAC4</td><td valign="top" align="center" rowspan="1" colspan="1">1502 &#x000b1; 109</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">HDAC9</td><td valign="top" align="center" rowspan="1" colspan="1">0.95 &#x000b1; 0.69</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">HDAC11</td><td valign="top" align="center" rowspan="1" colspan="1">26.91 &#x000b1; 19.12</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="2" colspan="1">Class IIb</td><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">HDAC6</td><td valign="top" align="center" rowspan="1" colspan="1">2.62 &#x000b1; 0.32</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">HDAC10</td><td valign="top" align="center" rowspan="1" colspan="1">1.14 &#x000b1; 0.76</td></tr></tbody></table></table-wrap></floats-group></article>
